Brief: Aurinia Pharma Reports Q3 And Nine-Months 2024 Results, Announces Restructuring To Focus On Lupkynis And AUR200

Aurinia Pharmaceuticals

07/11/2024 11:16

Nov 7 (Reuters) - Aurinia Pharmaceuticals Inc  AUPH.O :
    * AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE
MONTHS
2024 FINANCIAL AND OPERATIONAL RESULTS, ANNOUNCES STRATEGIC
RESTRUCTURING TO SHARPEN FOCUS ON CONTINUED LUPKYNIS® GROWTH AND
AUR200 DEVELOPMENT
    * AURINIA PHARMACEUTICALS INC - EXPECTS Q4 RESTRUCTURING
CHARGE OF
$15-$19 MILLION
    * AURINIA PHARMACEUTICALS INC - REITERATES 2024 NET PRODUCT
REVENUE GUIDANCE OF $210-$220 MILLION
    * AURINIA PHARMACEUTICALS INC - TO REDUCE WORKFORCE BY
APPROXIMATELY 45% IN RESTRUCTURING

Source text:  ID:nBw5JW1n2a 
Further company coverage:  AUPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))